Skip to main content
    C

    Coherus BioSciences Inc (CHRS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.51
    -0.02 (-3.73%)

    Market Cap: $81.21M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Coherus BioSciences Inc (CHRS) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Coherus BioSciences (CHRS) trades at 1.5x sales and 3.1x book value. Its P/S of 1.5x is below its 5-year median of 2.9x. Its forward P/E is 41.1x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/E41.1x
    Price to sales1.5x
    Price to book3.1x
    PEGN/A
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 55.9% below 3.4x.

    MultipleCurrent5-year median10-year median
    P/S1.5x2.9x3.4x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 117 months (10-year).

    Valuation History

    Over the 9 of the 10 year ends shown that have a P/S, its P/S ranged from 1.2x in 2023 to 153.9x in 2017.

    Year endPriceP/EP/SP/B
    2025$1.42N/A4.0x2.8x
    2024$1.38N/A6.0xN/A
    2023$3.33N/A1.2xN/A
    2022$7.92N/A2.9xN/A
    2021$15.96N/A3.7x12.5x
    2020$17.3810.7x2.7x5.4x
    2019$18.0114.8x3.7x13.4x
    2018$9.05N/AN/AN/A
    2017$8.80N/A153.9x16.8x
    2016$28.15N/A6.4x64.5x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About CHRS

    What is CHRS's forward P/E ratio?

    Coherus BioSciences has a forward P/E ratio of 41.1x.

    Is CHRS stock overvalued?

    GNG's valuation label for CHRS is Undervalued.

    What is CHRS's price to sales ratio?

    Coherus BioSciences has a price to sales ratio of 1.5x.